Clinical trial
Study to Evaluate the Immunogenicity and Safety of a Second Vaccination With the…
NCT00385840 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00385840 |
|---|---|
| Title | Study to Evaluate the Immunogenicity and Safety of a Second Vaccination With the Adjuvanted Influenza Vaccine Candidate |
| Official title | A Study to Evaluate the Immunogenicity, Safety and Reactogenicity of a Second Vaccination With the Adjuvanted Influenza Vaccine Candidate Compared to Fluarix™ Administered Intramuscularly in Elderly Aged 60 Years and Above. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Biological |
| Interventions | Influenza Vaccine GSK1247446A, FluarixTM |
| Enrollment | 678 |
| Start date | Oct 20, 2006 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 5, 2007 |
| First posted | Oct 11, 2006 |
| Last update posted | Jun 8, 2018 |
| Countries | Norway |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: